A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy (NCT03690388)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
🩺 Plain-English Summary (8th-Grade Level)
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (6 items).
Location: Exelixis Clinical Site #2 — Newport Beach, California
Age range: 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior treatment with any of the following: Cabozantinib; Selective small-molecule v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitor; More than 2 VEGFR-targeting TKI agents; More than 1 immune checkpoint inhibitor therapy; 1 systemic chemotherapy regimen (given as single agent or in combination with another chemotherapy agent)
- Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before randomization
- Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
- Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization.
- Known brain metastases or cranial epidural disease unless adequately treated
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (164 Sites)
Showing the first 25 of 164 sites.
- Exelixis Clinical Site #2 — Newport Beach, California
- Exelixis Clinical Site #98 — Sacramento, California
- Exelixis Clinical Site #69 — San Francisco, California
- Exelixis Clinical Site #10 — Stanford, California
- Exelixis Clinical Site #3 — Torrance, California
- Exelixis Clinical Site #9 — Aurora, Colorado
- Exelixis Clinical Site #21 — New Haven, Connecticut
- Exelixis Clinical Site #4 — Washington D.C., District of Columbia
- Exelixis Clinical Site #94 — Miami, Florida
- Exelixis Clinical Site #93 — Orlando, Florida
- Exelixis Clinical Site #6 — Tampa, Florida
- Exelixis Clinical Site #164 — Chicago, Illinois
- Exelixis Clinical Site #54 — Lexington, Kentucky
- Exelixis Clinical Site #153 — Boston, Massachusetts
- Exelixis Clinical Site #80 — Ann Arbor, Michigan
- Exelixis Clinical Site #78 — Detroit, Michigan
- Exelixis Clinical Site #22 — Detroit, Michigan
- Exelixis Clinical Site #63 — Columbia, Missouri
- Exelixis Clinical Site #42 — St Louis, Missouri
- Exelixis Clinical Site #11 — Omaha, Nebraska
- Exelixis Clinical Site #118 — Morristown, New Jersey
- Exelixis Clinical Site #76 — Charlotte, North Carolina
- Exelixis Clinical Site #19 — Durham, North Carolina
- Exelixis Clinical Site #7 — Cincinnati, Ohio
- Exelixis Clinical Site #5 — Bethlehem, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Differentiated Thyroid Cancer
- Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) — San Francisco, California
- Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer — San Francisco, California
Explore by condition: All Differentiated Thyroid Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.